20.500.12556/DiRROS-19413 Hyperthermia as a potential cornerstone of effective multimodality treatment with radiotherapy, cisplatin and PARP inhibitor in IDH1-mutated cancer cells Mutations in the isocitrate dehydrogenase 1 (IDH1MUT) gene occur in various types of malignancies, including ~60% of chondrosarcomas, ~30% of intrahepatic cholangiocarcinomas and >80% of low-grade gliomas. IDH1MUT are causal in the development and progression of these types of cancer due to neomorphic production of the oncometabolite D-2-hydroxyglutarate (D-2HG). Intracellular accumulation of D-2HG has been implicated in suppressing homologous recombination and renders IDH1MUT cancer cells sensitive to DNA-repair-inhibiting agents, such as poly-(adenosine 5′-diphosphate–ribose) polymerase inhibitors (PARPi). Hyperthermia increases the efficacy of DNA-damaging therapies such as radiotherapy and platinum-based chemotherapy, mainly by inhibition of DNA repair. In the current study, we investigated the additional effects of hyperthermia (42 °C for 1 h) in the treatment of IDH1MUT HCT116 colon cancer cells and hyperthermia1080 chondrosarcoma cancer cells in combination with radiation, cisplatin and/or a PARPi on clonogenic cell survival, cell cycle distribution and the induction and repair of DNA double-strand breaks. We found that hyperthermia in combination with radiation or cisplatin induces an increase in double-strand breaks and cell death, up to 10-fold in IDH1MUT cancer cells compared to IDH1 wild-type cells. This vulnerability was abolished by the IDH1MUT inhibitor AGI-5198 and was further increased by the PARPi. In conclusion, our study shows that IDH1MUT cancer cells are sensitized to hyperthermia in combination with irradiation or cisplatin and a PARPi. Therefore, hyperthermia may be an efficacious sensitizer to cytotoxic therapies in tumors where the clinical application of hyperthermia is feasible, such as IDH1MUT chondrosarcoma of the extremities. isocitrate dehydrogenase PARP hyperthermia D‐2‐hydroxyglutarate radiotherapy cisplatin izocitrat dehidrogenaza PARP hipertemija D‐2‐hidroksiglutarat radioterapija cisplatin true false true Angleški jezik Slovenski jezik Neznano 2024-07-17 03:57:50 2024-07-18 14:08:01 2024-07-19 03:45:50 0000-00-00 00:00:00 2022 0 0 Nasl. z nasl. zaslona; Opis vira z dne 20. 12. 2022; Ostali avtorji: Elia Prades-Sagarra, Sarah Saleh, Peter Sminia, Johanna W. Wilmink, Remco J. Molenaar, Hans Crezee and Cornelis J. F. van Noorden; Št. članka: 6228; str. [1]-13 iss. 24 Vol. 14 2022 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2022-12-17 576 2072-6694 10.3390/cancers14246228 134747651 https://doi.org/10.3390/cancers14246228 1 354046d8-43cf-11ef-b487-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=26777 RAZ_Khurshed_Mohammed_2022.pdf RAZ_Khurshed_Mohammed_2022.pdf 1 7647330C54A03C1C14AD2CA5BBA142A1 b7d6383cbb13e2eabc436ce96604895037b63a7ed746dd8f5c89e4f0b0b5f0bb edd38abb-44ed-11ef-b487-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=26911 Nacionalni inštitut za biologijo 0 0 0